SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) April 13, 2004
Cephalon, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 0-19119 | | 23-2484489 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
145 Brandywine Parkway
West Chester, Pennsylvania | | 19380 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code (610) 344-0200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On April 13, 2004, the Registrant announced that it will initiate a Phase III clinical program in the second half of 2004 evaluating GABITRIL® (tiagabine hydrochloride) for the treatment of anxiety disorders.
The Registrant hereby incorporates by reference the press releases dated April 13, 2004 attached hereto as Exhibit 99.1, and made a part of this Item 5.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial Statements of Business Acquired: Not applicable
(b) Pro Forma Financial Information: Not applicable
(c) Exhibits
Number | | Description |
99.1 | | Press Release – Cephalon, Inc. Announces Plans for Phase III Anxiety Program for Gabitril in 2004 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CEPHALON, INC. |
| |
| |
Date: April 13, 2004 | By: | /s/ John E. Osborn | |
| | John E. Osborn |
| | Senior Vice President, General Counsel &
Secretary |
3
EXHIBIT INDEX
Exhibit
Number | | Description |
| | |
99.1 | | Press Release – Cephalon, Inc. Announces Plans for Phase III Anxiety Program for Gabitril in 2004 |
4
